Kazia Therapeutics Limited American Depositary Shares
$10.39
-$0.47 (-4.33%)
$10.38Day Range$11.00
Key Statistics
Market Cap
$168.86M
Shares Outstanding
15.5M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Jan 6, 1999
Round Lot
100
Locale
US
Trading Data
Day Open
$10.89
Day High
$11.00
Day Low
$10.38
Volume
169.9K
VWAP
$10.57
Prev Close
$10.86
Transactions
--
Acc. Volume
--
About Kazia Therapeutics Limited American Depositary Shares
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
PHARMACEUTICAL PREPARATIONSSIC 28346 employees140 WICKS RD, NEW SOUTH WALES 2113, C3, 211301161298780088IPO Jan 6, 1999US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001075880
- Composite FIGI
- BBG000KC7878
- Share Class FIGI
- BBG001SCPMJ4
- Ticker Root
- KZIA
- SIC Code
- 2834
About Kazia Therapeutics Limited American Depositary Shares (KZIA) Stock
Kazia Therapeutics Limited American Depositary Shares (KZIA) closed the 2026-09-18 session at $10.39, down 4.33% versus the previous close (-0.47). The stock opened at $10.89 and traded between $10.38 and $11.00 during that session. Session trading volume was 170K shares. The volume-weighted average price (VWAP) is $10.57.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Kazia Therapeutics Limited American Depositary Shares has a market capitalization of $168.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. KZIA is listed on the XNAS exchange. The company employs approximately 6 people. Kazia Therapeutics Limited American Depositary Shares is headquartered in NEW SOUTH WALES 2113, C3. The recorded listing date is 1999-01-06.
On this page you can find market KZIA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.